Direkt zum Inhalt
Merck

Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.

The Journal of biological chemistry (2013-08-21)
Liang Dong, Narayan P Sharma, Brice J Jurban, William L Smith
ZUSAMMENFASSUNG

Prostaglandin endoperoxide H synthase-2 (PGHS-2), also known as cyclooxygenase-2 (COX-2), is a sequence homodimer. However, the enzyme exhibits half-site heme and inhibitor binding and functions as a conformational heterodimer having a catalytic subunit (Ecat) with heme bound and an allosteric subunit (Eallo) lacking heme. Some recombinant heterodimers composed of a COX-deficient mutant subunit and a native subunit (i.e. Mutant/Native PGHS-2) have COX activities similar to native PGHS-2. This suggests that the presence of heme plus substrate leads to the subunits becoming lodged in a semi-stable Eallo-mutant/Ecat-Native∼heme form during catalysis. We examined this concept using human PGHS-2 dimers composed of combinations of Y385F, R120Q, R120A, and S530A mutant or native subunits. With some heterodimers (e.g. Y385F/Native PGHS-2), heme binds with significantly higher affinity to the native subunit. This correlates with near native COX activity for the heterodimer. With other heterodimers (e.g. S530A/Native PGHS-2), heme binds with similar affinities to both subunits, and the COX activity approximates that expected for an enzyme in which each monomer contributes equally to the net COX activity. With or without heme, aspirin acetylates one-half of the subunits of the native PGHS-2 dimer, the Ecat subunits. Subunits having an S530A mutation are refractory to acetylation. Curiously, aspirin acetylates only one-quarter of the monomers of S530A/Native PGHS-2 with or without heme. This implies that there are comparable amounts of two noninterchangeable species of apoenzymes, Eallo-S530A/Ecat-Native and Eallo-Native/Ecat-S530A. These results suggest that native PGHS-2 assumes a reasonably stable, asymmetric Eallo/Ecat form during its folding and processing.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Guanidin -hydrochlorid, Molecular Biology, ≥99%
Sigma-Aldrich
Palmitinsäure, ≥99%
Sigma-Aldrich
Guanidin -hydrochlorid, organic base and chaeotropic agent, ≥99% (titration)
Sigma-Aldrich
Guanidin -hydrochlorid, ≥98%
Sigma-Aldrich
Indomethacin, 98.0-102.0%, meets EP testing specifications
Sigma-Aldrich
Guanidin -hydrochlorid -Lösung, BioUltra, ~8 M in H2O
Sigma-Aldrich
Palmitinsäure, BioXtra, ≥99%
Sigma-Aldrich
Arachidonsäure, >95.0% (GC)
Sigma-Aldrich
Guanidin -hydrochlorid -Lösung, Colorless liquid, 7.8 - 8.3 M, pH- 4.5 - 5.5
Supelco
Palmitinsäure, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Arachidonsäure, from non-animal source, ≥98.5% (GC)
Sigma-Aldrich
Guanidin -hydrochlorid, ≥99.0% (AT)
Supelco
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Palmitinsäure, ≥98%, FCC, FG
Sigma-Aldrich
Guanidin -hydrochlorid, BioUltra, Molecular Biology, ≥99.5% (AT)
Supelco
Palmitinsäure, analytical standard
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Palmitinsäure, ≥98% palmitic acid basis (GC)
Sigma-Aldrich
Guanidin -sulfat (Salz), 99%
Sigma-Aldrich
Naproxen, meets USP testing specifications
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Palmitinsäure, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Palmitinsäure, natural, 98%, FG
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthalinessigsäure, 98%
Supelco
Naproxen, VETRANAL®, analytical standard
Sigma-Aldrich
Flurbiprofen, cyclooxygenase inhibitor
Supelco
Naproxen -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Naproxen, European Pharmacopoeia (EP) Reference Standard
Supelco
Palmitinsäure, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Indomethacin, European Pharmacopoeia (EP) Reference Standard